Evolving Perspectives on the
Role of Beta-Blockers Across the
Risk Spectrum for Heart Disease

WebCAST CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

May 20, 2009

Expiration Date:

May 20, 2011

Intended Audience:

• Cardiologists
• Preventive cardiologists
• Hypertension specialists
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Specialists in invasive vascular management
• Program directors, cardiovascular medicine
• Fellows in cardiovascular medicine
• Clinical pharmacists and pharmacologists
• Phar macy directors (cardiovascular medicine)
• Investigators and clinical trial specialists
• Cardiovascular nurses

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Forest Pharmaceuticals.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Henry R. Black, MD – Program Chair
Clinical Professor of Medicine
New York University Medical Center
New York, NY

Grant/Research: Pfizer
Consultant: Forest Labs, Daiichi- Sankyo, MSD, Boerhinger-Ingelheim, Novartis, Gilead
Speaker’s Bureau: Sankyo, BI, Novartis, Pfizer

Michael A. Weber, MD
Professor of Medicine
SUNY Downtown College of Medicine
Brooklyn, NY

Consultant: Boehringer Ingelheim, BMS, Daiichi-Sankyo, Forest, Gilead, Merck, Novartis, Takeda
Speaker’s Bureau: Boehringer Ingelheim, BMS, Daiichi-Sankyo, Forest, GSK, Novartis, Sanofi- Aventis

Barry H. Greenberg, MD
Professor of Medicine
Director Advanced Heart Failure Program
University of California, San Diego
USCD Medical Center – San Diego, California

Consultant: GSK
Speaker’s Bureau: GSK

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn how to approach hypertension as a systematic disease, with multiple manifestations, and associations, including as sessment of coexisting conditions that support use of specific classes or agents.
• Learn how to apply evidence—based support for cardiose lective beta-blockers across the cardiovascular disease risk spectrum, including hypertension, symptomatic CHD, and heart failure.
• Learn how to manage complicated patients with high blood pressure, including those with ischemic heart disease and/or heart failure.
• Learn how to apply the results of landmark clinical trials and national guidelines to their clinical practice.
• Learn about the possible role of the new and emerging beta-1 cardioselective beta-blockers and their role in the manage ment of hypertension and related cardiovascular disorders, including heart failure and CVD.
• Learn how to apply evidence-based and guideline-consistent management of hypertension to specific patient subgroups.
• Learn about the effects of antihypertensive agents on myocar dial remodeling, heart failure, endothelial reactivity, endotheli al nitric oxide production and its metabolites on the pathogen esis of essential hypertension, CVD, and platelet activation; and, the possible implications for clinical management.
  
  

Disclaimer:

Copyright © 2009 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved